Acute reserpine administration elicits long-term spontaneous oral dyskinesia

European Journal of Pharmacology

Volumn 337, Issue 2-3, 1997, Pages 157-160

  Sussman, Amy N ^a   Tran Nguyen, Ly T L ^a   Neisewander, Janet L ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Dopamine; Oral dyskinesia; Reserpine; Tardive dyskinesia; Tongue protrusion

Indexed keywords

DOPAMINE; RESERPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DEPLETION; DRUG EFFECT; DYSKINESIA; MALE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TONGUE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE; DYSKINESIA, DRUG-INDUCED; MALE; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; TONGUE;

EID: 0030723086     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01271-5     Document Type: Article

References (13)

1. Baldessarini R.J., Cole J.O., Davis J.M., Simpson G., Tarsy D., Gardos G., Preskorn S.J. Tardive dyskinesia: Summary of a task force report of the American Psychiatric Association. Am. J. Psychiatry. 137:1980;1163-1172.
2. Gerlach J., Casey D.E. Tardive dyskinesia. Acta Psychiatr. Scand. 77:1988;369-378.
3. Gunne L.M., Andrén P.E. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: A glutamate hypothesis for tardive dyskinesia. Clin. Neuropharmacol. 16:1993;90-95.
4. Gunne L.M., Häggstrom J.E., Sjöquist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature. 309:1984;347-349.
5. Kazamatsuri H., Chien C.P., Cole J.O. Treatment of tardive dyskinesia. II. Short term efficacy of dopamine-blocking agents haloperidol and thiopropazate. Arch. Gen. Psychiatry. 27:1972;100-103.
6. Klawans H.L. The pharmacology of tardive dyskinesias. Am. J. Psychiatry. 130:1973;83-86.
7. Neisewander J.L., Lucki I., McGonigle P. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J. Pharmacol. Exp. Ther. 257:1991;850-860.
8. Neisewander J.L., Lucki I., McGonigle P. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res. 558:1991;27-35.
9. Neisewander J.L., Castañeda E., Davis D.A. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: Support for a model of tardive dyskinesia. Psychopharmacology. 116:1994;79-84.
10. Neisewander J.L., Castañeda E., Davis D.A., Elson H.J., Sussman A.N. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia. Eur. J. Pharmacol. 305:1996;13-21.
11. Shonecker M. Ein eigentumliches Syndrom in eralen Bereich bei Megaphen Applikation. Nervenartz. 28:1957;34.
12. Smith J.M., Baldessarini R.J. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch. Gen. Psychiatry. 37:1980;1368-1373.
13. Uhrbrand L., Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine, and electroconvulsive therapy. Psychopharmacologia. 1:1960;408-418.